hVIVO plc (LSE:HVO) announced that its client, Cidara Therapeutics, has reached an agreement to be acquired by Merck Sharp & Dohme LLC in a transaction valued at approximately $9.2 billion. The deal follows strong Phase IIb trial results for Cidara’s lead programme, CD388. hVIVO played a central role in advancing the candidate, generating essential clinical data and conducting large-scale field studies that supported its development. The acquisition underscores hVIVO’s strength in human challenge research and its expanding capabilities in field studies and laboratory services, reinforcing its leadership position in infectious disease research.
hVIVO’s outlook is supported by solid financial results and an appealing valuation, though bearish technical signals point to cautious near-term sentiment. Strong revenue growth and profitability remain key advantages, while a low P/E ratio and active dividend policy may attract value-focused investors despite the softer market momentum.
More about hVIVO plc
hVIVO plc is a full-service early-stage Contract Research Organisation (CRO) and a global leader in human challenge trial design and delivery. The company provides comprehensive clinical development services for biopharma clients, specialising in infectious and respiratory conditions. hVIVO operates a purpose-built quarantine facility in London and maintains subsidiaries in Germany and the Netherlands, offering early-phase trial execution, advanced virology and immunology lab services, and drug development consultancy.
Leave a Reply